244 related articles for article (PubMed ID: 15611635)
1. Dominant negative effects of the AML1/ETO fusion oncoprotein.
Fenske TS; Pengue G; Graubert TA
Cell Cycle; 2005 Jan; 4(1):33-6. PubMed ID: 15611635
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation.
de Guzman CG; Warren AJ; Zhang Z; Gartland L; Erickson P; Drabkin H; Hiebert SW; Klug CA
Mol Cell Biol; 2002 Aug; 22(15):5506-17. PubMed ID: 12101243
[TBL] [Abstract][Full Text] [Related]
3. Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice.
Fenske TS; Pengue G; Mathews V; Hanson PT; Hamm SE; Riaz N; Graubert TA
Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15184-9. PubMed ID: 15477599
[TBL] [Abstract][Full Text] [Related]
4. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia.
Higuchi M; O'Brien D; Kumaravelu P; Lenny N; Yeoh EJ; Downing JR
Cancer Cell; 2002 Feb; 1(1):63-74. PubMed ID: 12086889
[TBL] [Abstract][Full Text] [Related]
5. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
[TBL] [Abstract][Full Text] [Related]
6. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease.
Erickson PF; Dessev G; Lasher RS; Philips G; Robinson M; Drabkin HA
Blood; 1996 Sep; 88(5):1813-23. PubMed ID: 8781439
[TBL] [Abstract][Full Text] [Related]
7. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
[TBL] [Abstract][Full Text] [Related]
8. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells.
Mulloy JC; Cammenga J; MacKenzie KL; Berguido FJ; Moore MA; Nimer SD
Blood; 2002 Jan; 99(1):15-23. PubMed ID: 11756147
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model.
Rhoades KL; Hetherington CJ; Harakawa N; Yergeau DA; Zhou L; Liu LQ; Little MT; Tenen DG; Zhang DE
Blood; 2000 Sep; 96(6):2108-15. PubMed ID: 10979955
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.
Cho EK; Bang SM; Ahn JY; Yoo SM; Park PW; Seo YH; Shin DB; Lee JH
Korean J Intern Med; 2003 Mar; 18(1):13-20. PubMed ID: 12760263
[TBL] [Abstract][Full Text] [Related]
11. AML-1-ETO-Mediated erythroid inhibition: new paradigms for differentiation blockade by a leukemic fusion protein.
Choi Y; Elagib KE; Goldfarb AN
Crit Rev Eukaryot Gene Expr; 2005; 15(3):207-16. PubMed ID: 16390317
[TBL] [Abstract][Full Text] [Related]
12. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
[TBL] [Abstract][Full Text] [Related]
13. Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.
Steffen B; Serve H; Berdel WE; Agrawal S; Linggi B; Büchner T; Hiebert SW; Müller-Tidow C
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8448-53. PubMed ID: 12819347
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.
Li Y; Wang H; Wang X; Jin W; Tan Y; Fang H; Chen S; Chen Z; Wang K
Blood; 2016 Jan; 127(2):233-42. PubMed ID: 26546158
[TBL] [Abstract][Full Text] [Related]
15. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
16. AML1-ETO inhibits acute myeloid leukemia immune escape by CD48.
Wang Z; Guan W; Wang M; Chen J; Zhang L; Xiao Y; Wang L; Li Y; Yu L
Leuk Lymphoma; 2021 Apr; 62(4):937-943. PubMed ID: 33225787
[TBL] [Abstract][Full Text] [Related]
17. The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO.
Peterson LF; Yan M; Zhang DE
Blood; 2007 May; 109(10):4392-8. PubMed ID: 17284535
[TBL] [Abstract][Full Text] [Related]
18. Chaperonin TRiC/CCT Modulates the Folding and Activity of Leukemogenic Fusion Oncoprotein AML1-ETO.
Roh SH; Kasembeli M; Galaz-Montoya JG; Trnka M; Lau WC; Burlingame A; Chiu W; Tweardy DJ
J Biol Chem; 2016 Feb; 291(9):4732-41. PubMed ID: 26706127
[TBL] [Abstract][Full Text] [Related]
19. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.
Goyama S; Schibler J; Gasilina A; Shrestha M; Lin S; Link KA; Chen J; Whitman SP; Bloomfield CD; Nicolet D; Assi SA; Ptasinska A; Heidenreich O; Bonifer C; Kitamura T; Nassar NN; Mulloy JC
Leukemia; 2016 Mar; 30(3):728-39. PubMed ID: 26449661
[TBL] [Abstract][Full Text] [Related]
20. The ETO domain is necessary for the developmental abnormalities associated with AML1-ETO expression in the hematopoietic stem cell compartment in vivo.
de Guzman CG; Johnson A; Klug CA
Blood Cells Mol Dis; 2003; 30(2):201-6. PubMed ID: 12732184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]